| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response (NCT07284667) | ACADIA Pharmaceuticals Inc. | 2025-11-14 |
| Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis (NCT07095465) | ACADIA Pharmaceuticals Inc. | 2025-11-14 |
| Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis (NCT07029581) | ACADIA Pharmaceuticals Inc. | 2025-08-06 |
| ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study (NCT06194799) | ACADIA Pharmaceuticals Inc. | 2024-04-23 |
| OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome (NCT06420297) | ACADIA Pharmaceuticals Inc. | 2024-03-11 |
| Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome (NCT06173531) | ACADIA Pharmaceuticals Inc. | 2023-11-27 |
| ACP-204 in Adults With Alzheimer's Disease Psychosis (NCT06159673) | ACADIA Pharmaceuticals Inc. | 2023-11-14 |
| Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder (NCT05555615) | ACADIA Pharmaceuticals Inc. | 2022-11-02 |
| Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder (NCT05523895) | ACADIA Pharmaceuticals Inc. | 2022-08-09 |
| An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome (NCT04988867) | ACADIA Pharmaceuticals Inc. | 2021-09-22 |
| Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee (NCT05008835) | ACADIA Pharmaceuticals Inc. | 2021-07-20 |
| Open-Label Extension Study of Trofinetide for Rett Syndrome (NCT04776746) | ACADIA Pharmaceuticals Inc. | 2020-11-08 |
| Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (NCT04531982) | ACADIA Pharmaceuticals Inc. | 2020-08-05 |
| Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis (NCT04292223) | ACADIA Pharmaceuticals Inc. | 2020-02-10 |
| Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (NCT04279314) | ACADIA Pharmaceuticals Inc. | 2020-01-29 |
| Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDERâ„¢) (NCT04181723) | ACADIA Pharmaceuticals Inc. | 2019-11-06 |
| Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine (NCT04164758) | ACADIA Pharmaceuticals Inc. | 2019-10-23 |
| Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (NCT04000009) | ACADIA Pharmaceuticals Inc. | 2019-06-06 |
| Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (NCT03968159) | ACADIA Pharmaceuticals Inc. | 2019-04-25 |
| Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease (NCT03623321) | ACADIA Pharmaceuticals Inc. | 2018-07-17 |
| A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease (NCT03575052) | ACADIA Pharmaceuticals Inc. | 2018-05-21 |
| Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis (NCT03325556) | ACADIA Pharmaceuticals Inc. | 2017-09-27 |